Literature DB >> 26876342

Community-Based Multidisciplinary Computed Tomography Screening Program Improves Lung Cancer Survival.

Daniel L Miller1, William R Mayfield2, Theresa D Luu2, Gerald A Helms2, Alan R Muster2, Vickie J Beckler2, Aaron Cann2.   

Abstract

BACKGROUND: Lung cancer is the most common cause of cancer deaths in the United States. Overall survival is less than 20%, with the majority of patients presenting with advanced disease. The National Lung Screening Trial, performed mainly in academic medical centers, showed that cancer mortality can be reduced with computed tomography (CT) screening compared with chest radiography in high-risk patients. To determine whether this survival advantage can be duplicated in a community-based multidisciplinary thoracic oncology program, we initiated a CT scan screening program for lung cancer within an established health care system.
METHODS: In 2008, we launched a lung cancer CT screening program within the WellStar Health System (WHS) consisting of five hospitals, three health parks, 140 outpatient medical offices, and 12 imaging centers that provide care in a five-county area of approximately 1.4 million people in Metro-Atlanta. Screening criteria incorporated were the International Early Lung Cancer Action Program (2008 to 2010) and National Comprehensive Cancer Network guidelines (2011 to 2013) for moderate- and high-risk patients.
RESULTS: A total of 1,267 persons underwent CT lung cancer screening in WHS from 2008 through 2013; 53% were men, 87% were 50 years of age or older, and 83% were current or former smokers. Noncalcified indeterminate pulmonary nodules were found in 518 patients (41%). Thirty-six patients (2.8%) underwent a diagnostic procedure for positive findings on their CT scan; 30 proved to have cancer, 28 (2.2%) primary lung cancer and 2 metastatic cancer, and 6 had benign disease. Fourteen patients (50%) had their lung cancer discovered on their initial CT scan, 11 on subsequent scans associated with indeterminate pulmonary nodules growth and 3 patients who had a new indeterminate pulmonary nodules. Only 15 (54%) of these 28 patients would have qualified as a National Lung Screening Trial high-risk patient; 75% had stage I or II disease. Overall 5-year survival was 64% and 5-year cancer specific survival was 71% in the screened patients, whereas nonscreened lung cancer patients during that time in WHS had an overall survival of only 19% (p < 0.001).
CONCLUSIONS: A community-based multidisciplinary lung cancer screening program can improve survival of patients with lung cancer outside of a large multicenter study. This survival advantage was caused by a significant stage shift to earlier disease. Lung cancer CT screening may also benefit patients not meeting the National Lung Screening Trial criteria who are at moderate or high risk for lung cancer.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26876342     DOI: 10.1016/j.athoracsur.2015.11.001

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  11 in total

1.  Measures of outcome in lung cancer screening: maximising the benefits.

Authors:  Robert Peter Young; Raewyn Janice Hopkins
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

2.  Implementing computed tomography-based lung cancer screening in the community.

Authors:  James L Mulshine; Laurie Fenton Ambrose
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 3.  Quality assurance and quantitative imaging biomarkers in low-dose CT lung cancer screening.

Authors:  Chara E Rydzak; Samuel G Armato; Ricardo S Avila; James L Mulshine; David F Yankelevitz; David S Gierada
Journal:  Br J Radiol       Date:  2017-10-27       Impact factor: 3.039

4.  Synchronous primary lung sarcomatous carcinoma and lung squamous cell carcinoma: a case report.

Authors:  Maoyuan Zhao; Qiuyang Jing; Zhouguang Hui
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

Review 5.  Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Douglas E Wood; Ella A Kazerooni; Scott L Baum; George A Eapen; David S Ettinger; Lifang Hou; David M Jackman; Donald Klippenstein; Rohit Kumar; Rudy P Lackner; Lorriana E Leard; Inga T Lennes; Ann N C Leung; Samir S Makani; Pierre P Massion; Peter Mazzone; Robert E Merritt; Bryan F Meyers; David E Midthun; Sudhakar Pipavath; Christie Pratt; Chakravarthy Reddy; Mary E Reid; Arnold J Rotter; Peter B Sachs; Matthew B Schabath; Mark L Schiebler; Betty C Tong; William D Travis; Benjamin Wei; Stephen C Yang; Kristina M Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

6.  Stakeholder engagement to initiate lung cancer screening in an urban safety-net health system.

Authors:  Simon J Craddock Lee; Heidi A Hamann; Travis Browning; Noel O Santini; Suhny Abbara; David S Balis; Hsienchang Chiu; Brett A Moran; Molly McGuire; David E Gerber
Journal:  Healthc (Amst)       Date:  2019-08-31

Review 7.  Progress and prospects of early detection in lung cancer.

Authors:  Sean Blandin Knight; Phil A Crosbie; Haval Balata; Jakub Chudziak; Tracy Hussell; Caroline Dive
Journal:  Open Biol       Date:  2017-09       Impact factor: 6.411

8.  Economic burden of lung cancer: A retrospective cohort study in South Korea, 2002-2015.

Authors:  Soo Min Jeon; Jin-Won Kwon; Sun Ha Choi; Hae-Young Park
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

9.  Lung cancers and pulmonary nodules detected by computed tomography scan: a population-level analysis of screening cohorts.

Authors:  Caichen Li; Jing Liao; Bo Cheng; Jianfu Li; Hengrui Liang; Yu Jiang; Zixuan Su; Shan Xiong; Feng Zhu; Yi Zhao; Ran Zhong; Feng Li; Jianxing He; Wenhua Liang
Journal:  Ann Transl Med       Date:  2021-03

10.  Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003-2013.

Authors:  Dohun Kim; So Young Kim; Beomseok Suh; Jong Hyock Park
Journal:  Cancer Res Treat       Date:  2017-09-04       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.